Could GLP-1s Help Treat Depression and Anxiety?

You Should Know: It’s increasingly clear that GLP-1 drugs do more than change your waistline. In addition to potentially improving heart health and reducing the risk of substance use disorders, a growing body of research suggests they may also affect mental well-being. A 2026 study of more than 95,000 people with type 2 diabetes and anxiety or depression found that taking GLP-1 receptor agonists, including semaglutide (Ozempic and Wegovy), were associated with a lower risk of worsening mental health.

Going Deeper: The reasons aren’t fully understood. GLP-1 receptors are found throughout the brain, and these medications may influence inflammation, stress responses, and reward pathways involving dopamine. Better blood sugar control, physical health, and quality of life may also contribute. A 2026 meta-analysis of randomized trials found modest improvements in psychological well-being, but no significant improvement in depressive symptoms.

But there’s a wrinkle. A large 2024 observational study found GLP-1 use was associated with higher rates of depression, anxiety, and suicidal behavior. Other research has found no significant increased risk of psychiatric adverse events.

Takeaway: The evidence isn’t contradictory so much as incomplete. Different study designs can produce different answers, and researchers are still teasing apart direct brain effects from the mental-health benefits of feeling physically better.

Bottom Line: GLP-1s may have mental-health benefits, but they’re not established treatments for depression or anxiety. Consider the research promising, but very much a work in progress.